ImmunityBio Posts Record Q2 Revenue of $50.7M, Up 92% Year-Over-Year, with $357M in Cash
IBRX has more than doubled off its 52-week low of $1.95.
Summary
ImmunityBio posted record Q2 2026 product revenue of $50.7 million, up 92% year-over-year, with $357.4 million in cash. The GAAP loss was inflated by non-cash fair-value charges; adjusted loss improved. Key regulatory milestones include a January 2027 PDUFA date for papillary NMIBC and a planned sBLA submission for BCG-naïve NMIBC in 2026.
Updates
· SEC 10-Q — The 10-Q reports $672M in non-cash fair value losses for H1 2026, including $332.6M on the related-party convertible note and $339.6M on warrant liabilities, driving a six-month net loss of $863.2M.
Key Events · Earnings and Guidance · IBRX
-
Record Q2 Revenue
Net product revenue reached $50.7 million, a 92% increase year-over-year and 15% sequential growth from Q1 2026, marking the eighth consecutive quarter of growth since ANKTIVA's launch.
-
Strong Cash Position
Cash, cash equivalents, and marketable securities totaled $357.4 million as of June 30, 2026, providing runway to fund commercial and clinical priorities.
-
Non-Cash Fair-Value Losses
GAAP net loss of $230.4 million was primarily driven by $140.8 million in non-cash fair-value changes on warrant/derivative liabilities and a related-party convertible note due to a rising stock price. Adjusted net loss improved to $81.0 million from $89.9 million a year ago.
-
Regulatory Milestones
FDA accepted the sBLA for ANKTIVA in BCG-unresponsive NMIBC papillary disease with a PDUFA date of January 6, 2027. A second sBLA submission for BCG-naïve NMIBC is planned for 2026.
Analysis · IBRX · Life Sciences
ImmunityBio delivered its eighth consecutive quarter of sequential revenue growth, with Q2 product revenue hitting $50.7 million — a 92% jump from last year and 15% above Q1. The top-line beat is paired with a strong cash position of $357.4 million, which funds operations well into the clinical catalyst path. The GAAP net loss of $230.4 million is misleading: it is overwhelmingly driven by non-cash fair-value adjustments on warrants and convertible notes as the stock price rose, not cash burn. Adjusted net loss actually narrowed to $81.0 million. The FDA accepted the sBLA for papillary NMIBC with a January 2027 PDUFA date, and a second sBLA submission for BCG-naïve NMIBC is planned later this year — both are major label-expansion opportunities. Against a backdrop of a pending securities class action and insider selling, this quarter's commercial execution and regulatory progress provide a tangible counter-narrative.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IBRX was trading at $7.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5B. The 52-week trading range was $1.95 to $12.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.